We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bristol Myers Squibb’s Melanoma Antibody Combination Sees Success in Late-Stage Trial
Bristol Myers Squibb’s Melanoma Antibody Combination Sees Success in Late-Stage Trial
Bristol Myers Squibb (BMS) has announced that its phase 2/3 melanoma trial of the company’s anti-LAG-3 antibody combination therapy met its primary endpoint of extending progression-free survival for melanoma patients who had not received prior treatment.